Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy […]

The post Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma first appeared on 2 Minute Medicine.